Inhibitors of Phosphatidylinositol Kinases
Journal of Medicinal Chemistry, 2007, Vol. 50, No. 8 1971
(14) Griffin, R. J.; Fontana, G.; Golding, B. T.; Guiard, S.; Hardcastle,
I. R.; Leahy, J. J. J.; Martin, N.; Richardson, C.; Rigoreau, L.;
Stockley, M. L.; Smith, G. C. M. Selective benzopyranone and
pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent pro-
tein kinase: Synthesis, structure-activity studies, and radiosensiti-
zation of a human tumor cell line in vitro. J. Med. Chem. 2005, 48,
569-585.
(15) Leahy, J. J. J.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.;
Richardson, C.; Rigoreau, L.; Smith, G. C. M. Identification of a
highly potent and selective DNA-dependent protein kinase (DNA-
PK) inhibitor (NU7441) by screening of chromenone Libraries.
Bioorg. Med. Chem. Lett. 2004, 14, 6083-6087.
(16) Hardcastle, I. R.; Cockcroft, X.; Curtin, N. J.; El-Murr, M. D.; Leahy,
J. J. J.; Stockley, M.; Golding, B. T.; Rigoreau, L.; Richardson, C.;
Smith, G. C. M.; Griffin, R. J. Discovery of potent chromen-4-one
inhibitors of the DNA-dependent protein kinase (DNA-PK) using a
small-molecule library approach. J. Med. Chem. 2005, 48, 7829-
7846.
(17) Zhao, Y.; Thomas, H. D.; Batey, M. A.; Cowell, I. G.; Richardson,
C. J.; Griffin, R. J.; Calvert, A. H.; Newell, D. R.; Smith, G. C. M.;
Curtin, N. J. Preclinical evaluation of a potent novel DNA-dependent
protein kinase (DNA-PK) inhibitor, NU7441. Cancer Res. 2006, 66,
5354-5362.
by chromatography on silica, employing hexanes/EtOAc (20:1) as
eluent. Recrystallization from EtOH gave the title compound as an
off-white amorphous powder (3.96 g, 61%): mp 109-110 °C; IR
2969, 2896, 2857, 1647, 1556, 1467, 1447 cm-1; 1H NMR δ 3.44-
3.50 (m, 4H, CH2-N), 3.81-3.84 (m, 4H, CH2-O), 5.56 (d, 1H,
J ) 1.9 Hz, H-3), 6.32 (d, 1H, J ) 1.9 Hz, H-5), 6.33-7.66 (m,
7H-arom); LCMS (m/z) 396.2 [M + 1]+, 397.2 [M + 2]+, 398.2
[M + 3]+; HRMS (EI) [M + H]+ calcd for C21H17NO3S2, 396.0723;
found, 396.0721.
Enzyme Inhibition Assays. In vitro assays for DNA-PK
and ATM kinase activity were performed as described previ-
ously.14,39
Acknowledgment. We thank Adrian Moore for help
with the purification of the libraries, Cancer Research UK
for generous support, and BBSRC for the award of a student-
ship (to J.J.H.). The EPSRC Mass Spectrometry Service at
the University of Wales (Swansea) is also gratefully acknowl-
edged.
(18) Griffin, R. J.; Barbeau, O. R.; Golding, B. T.; Hardcastle, I. R.;
Smith, G. C. M; Richardson, C. Design and synthesis of novel
pyridopyrimidin-4-one and quinolin-4-one DNA-dependent protein
kinase (DNA-PK) inhibitors. Clin. Cancer Res. 2005, 11, 9051S.
(19) Take, Y.; Kumano, M.; Hamano, Y.; Fukatsu, H.; Taraoka, H.;
Nishimura, S.; Okuyama, A. OK-1035, a selective inhibitor of DNA-
dependent protein kinase. Biochem. Biophys. Res. Comm. 1995, 215,
41-47.
Supporting Information Available: Synthetic and analytical
data for compounds 11, 12, 17, 31, 32, 34, 36, 37, 40, 42-49,
51, 55-58, 60-67, 75, 77-81, 145B, and 147B. Elemental analyses
for all target compounds. This material is available free of charge
(20) Stockley, M.; Clegg, W.; Fontana, G.; Golding, B. T.; Martin, N.;
Rigoreau, L. J. M.; Smith, G. C. M.; Griffin, R. J. Synthesis, crystal
structure determination, and biological properties of the DNA-
dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydra-
zonomethyl-5-(4-pyridyl)pyrid-[1H]-2- one (OK-1035). Bioorg. Med.
Chem. Lett. 2001, 11, 2837-2841.
(21) Hollick, J. J.; Golding, B. T.; Hardcastle, I. R.; Martin, N.;
Richardson, C.; Rigoreau, L. J. M.; Smith, G. C. M.; Griffin, R. J.
2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of
DNA-dependent protein kinase (DNA-PK). Bioorg. Med. Chem. Lett.
2003, 13, 3083-3086.
(22) Morris, J.; Wishka, D. G. Synthesis of 2-amino-6-phenyl-pyran-4-
ones. Synthesis 1994, 43-46.
(23) Markl, G. Synthese von R,â-acetylencarbonsa¨uren durch innermole-
kulare Wittig-reaktion. Chem. Ber. 1961, 94, 3005-3010.
(24) Morris, J.; Luke, G. P.; Wishka, D. G. Reactions of phosgeniminium
salts with enolates derived from Lewis acid complexes of 2′-
hydroxypropiophenones and related â-diketones. J. Org. Chem. 1996,
3218-3220.
(25) Oikawa, Y.; Yoshioka, T.; Sugano, K.; Yonemitsu, O. Methyl
phenylacetylacetate from phenylacetyl chloride and Meldrum’s acid.
Org. Synth. 1984, 62, 198.
(26) Pak, C. S.; Yang, H. C.; Choi, E. B. Aminolysis of 5-acyl-2,2-
dimethyl-1,3-dioxane-4,6-diones (acyl Meldrum Acids) as a versatile
method for the synthesis of â-oxocarboxamides. Synthesis 1992,
1213-1214.
(27) Strakov, A. Ya.; Strautzele, M.; Strakova, I. A.; Gudriniece, E.
Enamines of 2-acetyl-1,3-cyclohexanediones. Latvijas PSR Zinatnu
Akademijas Vestis, Kimijas Serija 1967, 5, 563-566; Chem. Abstr.
1968, 69, 18659f.
(28) Schenone, P.; Bignardi, G.; Morasso, S. Reaction of sulfene with
heterocyclic R-dialkylaminomethyleneketones II. Synthesis of 5H-
1,2-oxathiino[5,6-c][1]benzopyran derivatives. J. Heterocycl. Chem.
1972, 9, 1341-1346.
(29) Datta, A.; Ila, H.; Junjappa, H. Reformatsky reaction on aroylketene
S,N-acetals: A facile route to 4-amino-6-aryl-2H-pyran-2-ones.
Synthesis 1988, 248-250.
(30) Maligres, P. E.; Waters, M. S.; Fleitz, F.; Askin, D. A highly catalytic
robust palladium catalyzed cyanation of aryl bromides. Tetrahedron
Lett. 1999, 40, 8193-8195.
(31) Dingwall, J.; Bentley, R. L.; Gainer, J.; Tuck, B. European Patent
Application 0 067124 B1, May 9, 1985.
References
(1) Smith, G. C. M.; Jackson, S. P. The PIKK family of protein kinases.
In Handbook of Cell Signaling; Elsevier Academic Press: New York,
2003; Vol. 1, pp 557-561.
(2) Shiloh, Y. ATM and related protein kinases: Safeguarding genome
integrity. Nat. ReV. Cancer 2003, 3, 155-168.
(3) Jackson, S. P. Sensing and repairing DNA double-strand breaks.
Carcinogenesis 2002, 23, 687-696.
(4) Smith, G. C. M.; Jackson, S. P. The DNA-dependent protein kinase.
Genes DeV. 1999, 13, 916-934.
(5) Abraham, R. T. Cell cycle checkpoint signaling through the ATM
and ATR kinases. Genes DeV. 2001, 15, 2177-2196.
(6) Kurimasa, A.; Kumano, S.; Boubnov, N. V.; Story, M. D.; Tung,
C. S.; Peterson, S. R.; Chen, D. J. Requirement for the kinase
activity of human DNA-dependent protein kinase catalytic subunit
in DNA strand break rejoining. Mol. Cell. Biol. 1999, 19, 3877-
3884.
(7) Rotman, G.; Shiloh, Y. ATM: From gene to function. Hum. Mol.
Genet. 1988, 7, 1555-1563.
(8) Deriano, L.; Guipaud, O.; Merle-Beral, H.; Binet, J. L.; Ricoul, M.;
Potocki-Veronese, G.; Favaudon, V.; Maciorowski, Z.; Muller, C.;
Salles, B.; Sabatier L, Delic, J. Human chronic lymphocytic leukemia
B cells can escape DNA damage-induced apoptosis through the non-
homologous end-joining DNA repair pathway. Blood 2005, 105,
4776-4783.
(9) Price, B. D.; Youmell, M. B. The phosphatidylinositol 3-kinase
inhibitor wortmannin sensitizes murine fibroblasts and human tumor
cells to radiation and blocks induction of p53 following DNA damage.
Cancer Res. 1995, 56, 246-250.
(10) Rosenzweig, K. E.; Youmell, M. B.; Palayoor, S. T.; Price, B. D.
Radiosensitization of human tumor cells by the phosphatidylinositol
3-kinase inhibitors wortmannin and LY294002 correlates with
inhibition of DNA-dependent protein kinase and prolonged G2-M
delay. Clin. Cancer Res. 1997, 3, 1149-1156.
(11) Boulton, S.; Kyle, S.; Yalcintepe, L.; Durkacz, B. W. Wortmannin
is a potent inhibitor of DNA double strand break but not single strand
break repair in Chinese hamster ovary cells. Carcinogenesis 1997,
17, 2285-2290.
(12) Kashishian, A.; Douangpanya, H.; Clark, D.; Schlachter, S. T.; Eary,
C. T.; Schiro, J. G.; Huang, H.; Burgess, L. E.; Kesicki, E. A.;
Hallbrook, J. DNA-dependent protein kinase inhibitors as drug
candidates for the treatment of cancer. Mol. Cancer Ther. 2003, 2,
1257-1264.
(32) Schroth, W.; Spitzner, R.; Kleinpeter, E. 2,4,6-Tris(dialkylamino)-
pyrilium salts and related systems, synthesis and reaction behaviour.
Tetrahedron Lett. 1988, 29, 4695-4698.
(13) Shinohara, E. T.; Geng, L.; Tan, J.; Chen, H.; Shir, Y.; Edwards, E.;
Hallbrook, J.; Kesicki, E. A.; Kashishian, A.; Hallahan, D. E. DNA-
dependent protein kinase (DNA-PK) is a molecular target for the
development of noncytotoxic radiation-sensitizing drugs. Cancer Res.
2005, 65, 4987-4992.
(33) Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P.
T.; Wymann, M. P.; Williams, R. L. Structural determinations of
phosphoinositide 3-kinase inhibition by wortmannin, LY294002,
quercetin, myricetin, and staurosporine. Mol. Cell 2000, 6, 909-
919.